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Abstract
Drug exposure during pregnancy constitutes a major legal issue and public health
concern. Drug and metabolite determination in biological matrices from mother and
newborn is an objective indication of prenatal drug exposure. However, limited data are
available regarding the interpretation of these analytical results in terms of window of
detection and degree of exposure. We collected paired maternal hair, meconium, placenta
and umbilical cord from 727 mother-newborn dyads. We analyzed these specimens by
liquid chromatography tandem mass spectrometry for the determination of cocaine,
opioids, methadone and amphetamines, and compared the analytical results from the four
different matrices. The cases were divided in non-exposure, low and frequent exposure,
based on maternal hair concentrations and segmental analysis by trimesters. For cocaine,
64 cases tested positive in hair, 9 in meconium, 6 in placenta and 7 in umbilical cord. In
the case of opioids, 14 maternal hair cases were positive, 11 meconium and umbilical
cord and 9 placenta samples. For methadone, 11 cases were positive in hair, 9 in
meconium and 6 in placenta and umbilical cord. For amphetamines, 18 cases were
positive according to maternal hair, but all meconium, placenta and umbilical cord tested
negative. Maternal hair was the most sensitive specimen to detect drug exposure during
pregnancy. Meconium, placenta and umbilical cord tested positive if hair concentrations
showed frequent drug use during the whole pregnancy, especially during the third
trimester. Meconium, placenta and umbilical cord also tested positive for morphine and
metabolites, if this drug was administered during labor and delivery.
Keywords: meconium, umbilical cord, placenta, cocaine, opioids

Introduction
The consumption of drugs of abuse during pregnancy not only constitutes a major public
health issue, but also an important legal concern. Prenatal exposure to drugs of abuse has
been associated with deleterious short- and long-term effects in the exposed children1, 2.
The type of harm depends on the trimester of the pregnancy. Heavy drug use during the
first trimester may result in abortions and malformations (teratogenic effects)3, 4. In the
second and third trimesters, the main harmful effects are related to fetal growth and
maturation. One of the most deleterious short-term effects is the neonatal abstinence
syndrome (NAS)5, and among the long-term effects, problems in neurodevelopment
(memory, attention, learning skills)6, 7. Gestational exposure to licit and illicit drugs is
considered the single largest preventable cause of in utero developmental compromise of
infants in the USA8. Early diagnosis and treatment achieves the best outcomes. Besides
the direct harm on the exposed children, the presence of drug use disorders in parents
increases the risk of child maltreatment by threefold or more9, 10.
In the USA and Europe, drug toxicology screening programs for pregnant women
and newborns continue to expand. However, evidence-based guidelines, policies for drug
screening/confirmation and referrals in this population are missing. The American
Congress of Obstetrics and Gynecology (ACOG) recommends universal drug screening
vs. risk-based screening, because the later tends to unfairly target low-income women11.
The treatment for these women and their detection is complicated because of the
involvement of the child welfare and legal systems by wide-ranging country statues,
some of which are clinical treatment oriented and some of which are punishment
oriented8. In the USA, the states of Alabama, South Carolina, and Tennessee have moved
to criminalize drug use during pregnancy. In Spain, it is under discussion12.
Although maternal interview is the most commonly employed method to detect
drug exposure during pregnancy, it is often unreliable due to the under-reporting 13. The
determination of drugs and metabolites in biological specimens from the mother (urine,
blood/plasma, oral fluid, sweat), from the newborn (urine, meconium and hair) and from
the fetal-maternal unit (amniotic fluid, placenta and umbilical cord) offers an objective
evidence of this exposure. Previously published reviews discussed the advantages and
disadvantages of some of these matrices14-19; however, data about the alternative matrices
placenta and umbilical cord are scarce18. Also the interpretation of the analytical results
of the neonatal biological samples in terms of window of detection and degree of
exposure is still not well established.
Maternal hair analysis shows the longest window of detection. Taking into
account that hair grows at an accepted rate of 1 cm/month20, segmental hair analysis can
describe the drug exposure throughout the whole pregnancy. Other biological specimens
from the mother, such as blood, oral fluid and urine, show a much shorter window of
detection (blood and oral fluid hours, and urine days). Among the different specimens
from the newborn, meconium, the first stool of an infant, is nowadays considered the
“gold standard” to reflect drug exposure during the third trimester18. However, its
expulsion may take up to 5 days after delivery, or it could be passed in utero, making this
matrix unavailable for drug testing. Placenta and umbilical cord offer the advantages of
being available at birth and in adequate amount for analysis. However, data about drug
and metabolite concentrations and window of detection is limited18, 21.

We collected and analyzed paired biological samples from 727 mother and
newborn dyads, including maternal hair, meconium, placenta and umbilical cord, to study
drug exposure to cocaine, opioids, methadone and amphetamines during pregnancy.
Maternal hair was employed as reference to establish the timing and the degree of
exposure to the drugs of interest. These biological samples (maternal hair, meconium,
placenta and umbilical cord) were compared in terms of windows of detection, analyte
and metabolite profile and predominant analytes, and concentrations.
Materials and Methods
Participants
The participants were pregnant women who delivered at the University Hospitals of
Santiago de Compostela and Vigo, Spain, from January 2012 to December 2015. The
participants were informed about the study both in writing and orally before the delivery,
and they gave written consent. The subjects were not paid for their participation. The
study was approved by the Ethics Committee of the University of Santiago de
Compostela, Spain. Eight hundred fifty eight pregnant women agreed to participate in the
study. All biological specimens (maternal hair, meconium, placenta and umbilical cord)
were collected in 727 cases.
Specimen Collection and Storage
The entire term placenta and umbilical cord specimens were collected at delivery in a
polypropylene container and stored at -20°C until analysis. Meconium specimens were
collected from newborn diapers up to 3 days after delivery in polypropylene containers
and also stored at -20°C until analysis. Maternal hair specimens (a lock of about 100
hairs) were collected after the delivery from the vertex posterior region, as close as
possible from the scalp and tied up at the root. These specimens were stored protected
from the light at room temperature until analysis.
Specimen Analysis
All maternal hair specimens and meconium specimens were analyzed for cocaine,
opiates, methadone and amphetamines. Umbilical cord and placenta were analyzed if
either maternal hair or meconium specimens tested positive for any drug or metabolite.
Maternal hair, whenever possible based on the length and amount of hair
available, was segmented by trimesters. Each lock of hair was measured, and divided into
3 segments corresponding to the 3 trimesters: segment 1 (2 cm long) from 0 (root) to 2
cm for the 3rd trimester; segment 2 (3 cm long) from 3 to 5 cm for the 2nd trimester; and
segment 3 (3 cm long) from 6 to 8 cm for the 1st trimester. If the amount of hair was not
enough for segmentation, only 1 segment up to 8 cm long was analyzed (whole
pregnancy).
Maternal hair22, meconium21 and placenta and umbilical cord23 were analyzed by
previously published liquid chromatography tandem mass spectrometry (LC-MSMS)
methods. Briefly, hair specimens were analyzed for 35 licit and illicit drugs in 50 mg of

hair, including cocaine, opioids, methadone and amphetamines. Hair decontamination
was performed with dichloromethane and incubation in 2 mL acetonitrile overnight at
50°C. The extraction procedure consisted in a liquid-liquid extraction
(hexane:ethylacetate, 55:45 v/v, at pH 9), followed by reversed-phase solid phase
extraction (Strata-X cartridges, Phenomenex, Torrance, CA). Reversed-phase
chromatographic separation was performed in an Atlantis T3 2.1x100 mm 3 µm column
(Waters, Milford, MA), with acetonitrile and ammonium formate pH 3 as mobile phase
and a 32 minute of total run time. The method was linear from 0.5-100 to 2,000-20,000
pg/mg, depending on the compound, and the limit of detection (LOD) was 0.5-100
pg/mg.
Placenta and umbilical cord were analyzed for the determination of opioids
(morphine, morphine-3-glucuronide, morphine-6-glucuronide, codeine, 6-acetilmorphine
(6 AM)), amphetamines (amphetamine, methamphetamine, 3,4methylenedioxyamphetamine(MDA), 3,4-methylenedioxymethamphetamine
(MDMA)), cocaine (cocaine, benzoylecgonine (BE), ecgonine methyl ester (EME),
hydroxy-benzoylecgonine (OH-BE)) and methadone (methadone, and 2-ethylidene-1,5dimethyl-3,3-diphenylpyrrolidine (EDDP)). One gram (±0.02 g) of placenta or umbilical
cord was homogenized in 5 mL of water with the Ultra-Turrax T8 dispenser (IKA,
Staufen, Germany). After the addition of 50 µL of 10% formic acid and centrifugation,
the supernatants were submitted to cation exchange solid phase extraction (OASIS MCX
cartridges, Waters). Chromatographic separation was performed in an Atlantis T3 2.1 x
100 mm 3 µm column (Waters), acetonitrile and 0.1% formic acid as the mobile phase,
and 18 minutes of total run time. The linearity ranged from 1-2.5 ng/g to 100-500 ng/g,
and the LOD was 0.5-2.5 ng/g, depending on the compound.
Meconium was analyzed for the same drugs and metabolites as placenta and
umbilical cord. In this case, 0.5±0.01 g of meconium was pretreated with 2 mL of
methanol + 0.01% formic acid, and mixed in a rotor for 30 minutes. After centrifugation,
the supernatant was evaporated to dryness and reconstituted in 200 µL methanol and 2
mL of 0.1% formic acid. This solution was submitted to cation exchange solid phase
extraction (OASIS MCX cartridges, Waters). Chromatographic separation was performed
in an Atlantis T3 2.1 x 100 mm 3 µm column (Waters), acetonitrile and formic acid 0.1%
as mobile phase, and 18 minutes of the total run time. The LOD was 0.5-2.5 ng/g,
depending on the compound, and the linearity was from 5 to 500 ng/g. Supplemental
Table 1 summarizes the LOD, LOQ and cutoffs for each analyte for each specimen.
Comparison of Hair, Meconium, Placenta and Umbilical Cord
To compare the different matrices, we considered maternal hair as the reference matrix.
We classified the degree of exposure based on hair concentrations in “frequent
exposure”, “low exposure” and “non-exposure”. For “frequent exposure” we used the
cutoff values recommended by the Society of Hair Testing (SoHT) for opioids (morphine
or 6-AM at 200 pg/mg), for cocaine (cocaine at 500 pg/mg and BE at 50 pg/mg), and for
amphetamines (amphetamine, methamphetamine, MDA or MDMA at 200 pg/mg). In the
case of methadone we established the cutoff at 200 pg/mg, similar to opioids. For “low
exposure” we employed the method’s LOQ for the compounds of interest (20 pg/mg) up
to SoHT cutoff values. “Non-exposure” specimens were the cases where drugs were

negative. For meconium, placenta and umbilical cord, the specimens were considered
positive for any drug if the concentration was above the methods’ LOQ (1-5 ng/g).
Results
Cocaine
Sixty-two cases were positive for cocaine in hair (8.7% of total samples). Thirty-four
specimens out of 62 could be segmented by trimesters, corresponding to the first, second
and third trimester, and in 28 cases only one segment 8 cm long, reflecting the whole
pregnancy, was analyzed. The concentrations in the segmented specimens (n=34 cases)
were cocaine 20-24,275 pg/mg (n=76 segments), BE 20-15,355 pg/mg (n=74 segments)
and cocaethylene 20-281 pg/mg (n=11 segments). Eight cases showed at least one of the
3 segments with concentrations above the SoHT cocaine cutoff; 4 cases showed all the
three segments above SoHT cutoff, 3 cases showed only the third segment (first
trimester) above the cutoff, and one case the second and the third segments (first and
second trimester). With regard to the one segment specimens, the concentrations were
cocaine 31-22,390 pg/mg (n = 29 samples), BE 34-23,730 pg/mg (n = 29 samples) and
cocaethylene 20-361.5 pg/mg (n = 9 samples). Thirteen samples showed concentrations
above the SoHT cocaine cutoff.
Nine meconium specimens were positive for cocaine and metabolites (1.2% of
total samples). OH-BE was detected in all samples (n=9) at concentrations 10-321 ng/g.
EME (4-517 ng/g), BE (2-428 ng/g) and cocaine (5-111 ng/g) were detected in 8 samples,
and cocaethylene (3-95.3 ng/g) in 3 samples. Placenta and umbilical cord were analyzed
for cocaine and metabolites if hair (n=62) or meconium (n=9) were positive. Six placenta
specimens were positive for cocaine metabolites (0.96% of total samples). EME was
positive in 6 samples (1-7 ng/g), BE in 5 cases (1-24 ng/g) and OH-BE in one at 1 ng/g.
All placenta samples were negative for cocaine and cocaethylene. Seven umbilical cord
samples were positive for cocaine and metabolites. EME was positive in 6 samples (1-5.5
ng/g), BE in 6 samples (1-39.3 ng/g) and cocaine in 2 cases (2.4-6.2 ng/g). All umbilical
cord samples were negative for OH-BE and cocaethylene. These results are summarized
in Table 1.
Segmental analysis could be performed in 34 hair samples. If all hair segments
were above the SoHT cutoff (n=4 cases), which reflected “frequent exposure” throughout
the whole pregnancy, the 3 matrices, meconium, placenta and umbilical cord, were
positive for cocaine and metabolites. If one or two hair segments, corresponding with the
first and/or second trimesters, were above the SoHT cutoff (n=4), meconium, placenta
and umbilical cord tested negative for cocaine and metabolites. In all other cases, if hair
concentrations were positive but below SoHT cutoff or negative, all meconium, placenta
and umbilical cord were negative (Figure 1).
Twenty-eight hair samples could not be divided in segments, and one 8 cm long
segment was analyzed. Thirteen of those cases showed concentrations above the SoHT
cutoff. Among these cases, 5 meconium samples were positive for cocaine and
metabolites, 3 umbilical cord and 2 placenta samples. If the 8 cm long segment
concentrations were below SoHT or negative, all meconium, placenta and umbilical cord
were negative (Figure 1).

Comparing meconium, placenta and umbilical cord concentrations and metabolite
profile, meconium was the matrix that showed the highest concentrations followed by
umbilical cord and placenta. The predominant metabolite in meconium was OH-BE and
in placenta and in umbilical cord was BE.
Opioids
Fourteen cases were positive for opioids (morphine, codeine, 6-AM) in hair (1.9% of
total cases). Nine cases could be analyzed in 3 segments, while in 5 cases only one 8 cm
long segment could be analyzed. The concentration ranges in the segmented cases were
morphine 30-624 pg/mg (n=10 segments), codeine 20-59 pg/mg (n=6 segments), and 6AM 20-1,258 pg/mg (n=10 segments). Six cases showed at least one segment above the
SoHT opioids cutoff; in one case all three segments were above the cutoff, and in 5 cases
the second segment that corresponded with the second trimester was above the cutoff.
The 8 cm long hair segments showed morphine at 20-284.4 pg/mg (n=4), codeine 20
pg/mg (n=3) and 6-AM 28.8-155.5 pg/mg (n=4). Two of these samples were above the
SoHT cutoff.
Eleven meconium samples were positive for opioids. Morphine was detected in
all cases (5-109.2 ng/g), morphine-3-glucuronide in 4 cases (5.4-53.2 ng/g), and
morphine-6-glucuronide in 2 cases (1.6-5 ng/g). 6-AM and codeine were not detected in
any sample. Nine placenta samples tested positive for opioids. Morphine and morphine3-glucuronide were positive in all cases (1-4.6 ng/g and 10.2-40 ng/g, respectively) and
morphine-6-glucuronide in 3 cases (1.3-8.1 ng/g). Codeine and 6-AM were not detected
in any sample. Eleven umbilical cord samples were positive for opioids. Morphine and
morphine-3-glucuronide were detected in all the specimens (morphine 1-18.9 ng/g,
morphine-3-glucuronide 8.8-95.8 ng/g) and morphine-6-glucuronide in 8 cases (2-11.1
ng/g). Codeine and 6-AM were not detected in any of the umbilical cord samples. These
results are summarized in Table 2.
Nine hair samples were analyzed in 3 segments corresponding to the different
trimesters during pregnancy. One case showed hair concentrations above the SoHT
opioids cutoff for all the segments, and meconium, placenta and umbilical cord were
positive. The predominant analyte in meconium was morphine, and in placenta and
umbilical cord was morphine-3-glucuronide. In five cases, only the second segment,
reflecting the second trimester, was above the SoHT cutoff, and all the 3 matrices were
negative. Among the 8 cm long hair segments, 2 cases showed concentrations above the
SoHT cutoff, and meconium, placenta and umbilical cord were negative (Figure 2).
In 10 cases, although maternal hair opioid analysis was negative, meconium,
placenta and/or umbilical cord tested positive for morphine and/or its metabolites,
morphine 3- and 6-glucuronide. In all these cases morphine was administered to the
mother in the hospital during labor and delivery.
Methadone
Eleven cases out of 727 were positive for methadone in hair (1.5% of total). Six cases
could be submitted for segmental analysis, and 5 were analyzed in one segment of 8 cm.
The segmented samples showed methadone from 42.7-14,776.1 pg/mg (n=18 segments),

and the one segment samples showed methadone in the range 55.1-3,838 pg/mg (n=5).
Nine meconium samples were positive for methadone exposure. EDDP was
detected in all cases with concentrations from 14.6 to 6,049 ng/g, and methadone in 7
samples with concentrations from 244.5 to 3,926 pg/mg. Placenta and umbilical cord
were positive in 6 cases, being methadone and EDDP detected in all samples. For
placenta, methadone concentrations ranged from 42.1 to 366.3 ng/g and EDDP from 5.1
to 1,975 ng/g. In the case of umbilical cord, methadone concentrations were 4.3-763 ng/g
and EDDP 1-143.2 ng/g. Meconium showed higher concentrations compared to placenta
and umbilical cord. The predominant analyte in meconium was the metabolite EDDP, but
in most placenta and in all umbilical cord samples it was methadone. These results are
summarized in Table 3.
Meconium, placenta and umbilical cord tested positive if all the 3 hair segments
throughout pregnancy were positive for methadone, regardless if these concentrations
were above or below the 200 pg/mg cutoff (all 3 hair segments concentrations ≥ 42.7
pg/mg). In the case of one segment samples, if methadone concentrations were above the
“200 pg/mg” cutoff (n=3), all meconium samples were positive, 2 placenta and 2
umbilical cord samples. If methadone hair concentrations were below 200 pg/mg (n=2),
meconium, placenta and umbilical cord were negative (Figure 3).
Amphetamines
In the case of the amphetamines, 18 cases were positive in hair (2.5% of total cases). Ten
could be analyzed in segments, and 8 cases were analyzed as one 8 cm segment. In the
segmented samples, the analytes detected were amphetamine (33.4-1,204 pg/mg, n=9
segments), methamphetamine (24.2-130 pg/mg, n=5 segments), MDA (65.6-189 pg/mg,
n=3 segments) and MDMA (39.4-191.3 pg/mg, n=6 segments). The concentrations in the
one segment samples were amphetamine (53.2-1,899 pg/mg, n=6), methamphetamine
(37.8-137.4 pg/mg, n=4), MDA (78.3-118.4, n=2) and MDMA (38-209.8 pg/mg, n=5).
Among the segmented cases, only in one case one segment corresponding with
the first trimester of pregnancy showed amphetamine concentrations above SoHT cutoff.
All the meconium, placenta and umbilical cord samples tested negative. Although in the
case of one segment hair samples, 3 cases showed amphetamine concentrations above the
established cutoff and one MDMA case was above the cutoff, all meconium, placenta and
umbilical cord tested negative.
Discussion
We analyzed biological matrices from 727 mother-newborn dyads for the determination
of cocaine, opioids, methadone and amphetamines collected from 2012 to 2015. The goal
of the study was to compare maternal hair, meconium, placenta and umbilical cord in
terms of windows of detection, predominant analytes and metabolites detected, and
concentrations. Maternal hair was considered the reference matrix to establish the drugs
consumed, timing and degree of exposure (non-exposure, low or sporadic and frequent),
and all the cases were analyzed for the drugs of interest. Also meconium was analyzed in
all cases because this is the current “gold standard” matrix to detect in utero drug
exposure. We explored placenta and umbilical cord as an alternative to detect drug

exposure during pregnancy. Placenta and umbilical cord were analyzed if either maternal
hair or meconium specimens were positive to any drug (n=124). The authors performed a
pilot study in 2011 with 175 cases, which results were previously published21. In that
study, 21 cases were positive for cocaine (12%), 2 for opioids (1.1%), 5 for methadone
(2.9%) and one for amphetamines. Due to the limited number of positive specimens, the
study was underpowered. The present work with a larger cohort (727 mother-newborn
dyads) was conducted to establish valid observations.
The analytical determination of drugs and/or metabolites in different biological
matrices from the mother and the newborn offers an objective identification of drug
exposure during pregnancy. The interpretation of the analytical results in the different
biological matrices tries to determine when the exposure happened during the pregnancy
(first, second or third trimester), for how long (sporadic or frequent) and what amount of
drugs were consumed by the mother. Maternal hair shows the longest window of
detection and it has been used to monitor drug exposure during pregnancy19. Maternal
hair is considered the most sensitive specimens to detect drug consumption during this
period18, 24. In the present study, also maternal hair was the most sensitive biological
sample to detect drug use or abuse during the whole pregnancy. In addition, as we
showed in this study, hair was useful to differentiate between mother use and drugs
administered during labor and delivery (opioids hair test negative vs. opioids positive in
meconium, placenta and umbilical cord). Despite its usefulness, maternal hair monitoring
is not a direct maker of in utero drug exposure, and in some countries, such as the USA,
still is required a newborn specimen as evidence of child abuse25.
Meconium has become the “gold standard” for drug exposure detection in
newborns. Because its formation starts around the 12th week of gestation and it
accumulates until birth, it was considered that it reflected drug exposure during the
second and third trimester14, 15. However, it is known that its formation increases during
the last trimester (week 28 – 40), and about 75% of meconium is produced during the last
8 weeks of pregnancy26. Because of this, meconium results may reflect just the last 2-3
months of pregnancy27. Previous studies also showed that not just the timing but also the
frequency of drug exposure was critical to be able detect drugs in meconium. A frequent
and chronic exposure is necessary to produce meconium positive results 21, 28. Our results
are in agreement with these previous studies. Meconium only was positive if a frequent
drug abuse was documented by hair analysis during the whole pregnancy for cocaine,
opioids and methadone, especially during the third trimester.
Umbilical cord tissue is an emerging specimen of considerable interest. Its
collection is easy and noninvasive, and compared to meconium it offers the advantages of
abundant amount of specimen and readily available at delivery. However, few studies
about umbilical cord fully describing this matrix to detect in utero drug exposure
(predominant analytes and metabolites, concentrations and windows of detection) are
available18. Recently, Marin et al29 developed a screening method of 57 drugs in
umbilical cord tissue by liquid-chromatography time-of-flight (TOF) mass spectrometry,
and compared paired umbilical cord and meconium samples (n=7). Conflicting results
were obtained, and only 2 cases showed meconium-umbilical cord good matching results.
Jones et al30 developed a method for the detection of heroin exposure in umbilical cord.
The identification of heroin exposed newborns improved due to the monitoring of
meconin, a metabolite of the illicit heroin contaminant noscapine. No comparison with

other specimens was performed. Our present data show that umbilical cord tissue could
be an alternative to meconium; however, more sensitive analytical techniques are
required due to the lower concentrations detected in this biological sample. It is important
to highlight the differences between the most predominant analyte and/or metabolites
between these matrices. In the case of cocaine, the most prevalent and/or abundant
compound was OH-BE in meconium and BE in umbilical cord. With regard to the
opioids, our results showed that it is critical to monitor morphine-3-glucuronide in the
case of umbilical cord. This incorporation of glucuronides in umbilical cord samples has
been indicated previously 21, 31. Methadone was the predominant metabolite in umbilical
cord, while the EDDP was the target compound in meconium32. In the present study,
meconium and umbilical cord positive results agreement was 60% for cocaine, 100% for
opioids and 70% for methadone.
Several studies have been published about placenta as alternative matrix to detect
in utero drug exposure21, 33, 34. Falcon et al34 compared maternal hair with placenta and
fetal remains from abortions at the 12th week of gestation. In that study hair was more
sensitive than placenta to detect cocaine (20% placenta positive) and opiates (none
placenta positive) exposure. Previous comparisons between meconium, umbilical cord
tissue and placenta showed that placenta performed similar to umbilical cord and both
matrices were less sensitive than meconium for cocaine and opiates21, 32, 33. In the present
study a better agreement among meconium and placenta results were observed.
Meconium and placenta positive results agreement was 60% for cocaine, 81.8% for
opioids, and 70% methadone. As reported before21, 33, we found that placenta
concentrations were 5 to 10-fold lower than meconium concentrations, and the
predominant compound were different in placenta compared to meconium (Tables 1-3),
suggesting a higher accumulation happens in meconium. However, this behavior may be
the opposite for other compounds such as caffeine and theobromine35 and
benzodiazepines29, 36.
The anatomical/physiological differences of these matrices and the physicochemical properties of the drugs and metabolites may influence the different
incorporation of drugs and metabolites in meconium, umbilical cord and placenta. We
observed a tendency of higher accumulation of more polar compounds in umbilical
cord/placenta and more apolar compounds in meconium for some drug groups, such as
opioids. All these information should bear in mind in the development of analytical
methods in the different matrices to select the appropriate target compounds and
concentration range.
Cocaethylene is a specific metabolite that is formed if cocaine and ethanol are
consumed simultaneously. Meconium samples were positive for cocaethylene in 3 cases,
where the hair concentration was above 131 pg/mg in the third trimester (segment 1) or
above 180 pg/mg during the whole pregnancy (8 cm segment). In these cases, placenta
and umbilical cord were negative for this metabolite. Other alcohol biomarkers, such as
fatty acid ethyl esters and ethyl glucuronide and sulfate, have being detected in
meconium37; however, umbilical cord and placenta data are scarce38, 39. Unfortunately,
other alcohol biomarkers were not investigated in the present study.
Meconium, umbilical cord and placenta reflected drug exposure during
pregnancy, but also it is important to highlight that they may reflect drugs administered
during labor and delivery. This fact has been reported previously in meconium and

umbilical cord29, 40, but there is no data about placenta. In the present study we detected
10 cases that tested positive for morphine and metabolites in these three alternative
matrices, due to the administration of morphine to the mother during labor and delivery.
The analysis of maternal hair samples excluded opioids use during pregnancy. Although
meconium also has been reported positive if drugs were administered to the newborn40,
the employment of umbilical cord and placenta would exclude these cases.
A limitation of this study could be that not all placenta and umbilical cord
samples were analyzed, and therefore a completely comparison with hair and meconium
could not be performed. In order to optimize laboratory resources and to be able to
analyze the highest number of cases as possible to obtain significant results (n=727),
placenta and umbilical cord samples were analyzed if either hair or meconium were
positive to any of the investigated drugs or metabolites (n=124). Following the present
approach, we could have missed cases where hair and meconium were negative, and
placenta and/or umbilical cord were positive, but based on previous studies21,28, this
number is probably marginal and it would not affect the obtained results. Another
observation of the present study was that higher concentrations were found in meconium
compared to placenta and umbilical cord. Even though the employed placenta and
umbilical cord cutoffs (1-2.5 ng/g) were lower than meconium cutoffs (5 ng/g), the
development of more sensitive analytical methods in placenta and umbilical cord could
have increased the number of positive cases detected.
Conclusion
We presented the most comprehensive study to date comparing maternal hair, meconium,
placenta and umbilical cord for the detection of drug exposure during pregnancy.
Maternal hair is the most sensitive matrix to detect cocaine, opioids, methadone and
amphetamines use and/or abuse during the three trimesters. Meconium, placenta and
umbilical cord reflect drug exposure if the mother drug use was frequent and during the
whole pregnancy, specially the third trimester. Attention should be paid to the drugs
administered during labor and delivery, because meconium, placenta and umbilical cord
may test positive.
This project was supported by the Ministerio de Sanidad, Plan Nacional Sobre Drogas,
Gobierno de España 2011/097. None of the authors have any conflict of interest to
disclose.
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Table 1. Quantitative results for cocaine and its metabolites benzoylecgonine (BE),
hydroxy-BE (OH-BE), ecgonine methyl esther (EME) and cocaethylene (CE) in
meconium (n=9 total positive cases), placenta (n=6 total positive cases) and umbilical
cord (n=7 total positive cases).
Matrix

Cocaine (ng/g)

BE (ng/g)

OH-BE (ng/g)

EME (ng/g)

CE (ng/g)

Meconium

5 -111
(n=6)
0

10 – 321
(n=10)
1
(n=1)

Umbilical
Cord

2.4-6.2
(n=2)

4 – 517
(n=9)
1–7
(n=6)
1 – 5.5
(n=6)

3 – 95.3
(n=3)

Placenta

2 – 428
(n=9)
1 – 24
(n=6)
1 – 39.3
(n=6)

0

0
0

Table 2. Quantitative results for morphine, morphine-3-glucuronide (M-3-Gluc) and
morphine-6-glucuronide (M-6-Gluc) in meconium (n=11 total positive cases), placenta
(n=9 total positive cases) and umbilical cord (n=11 total positive cases). 6monoacetylmorphine (6-AM) and codeine were not detected in any specimen.
Matrix
Meconium
Placenta
Umbilical
Cord

Morphine (ng/g)

M-3-Gluc (ng/g)

M-6-Gluc (ng/g)

5 – 109.2
(n=11)
1 – 4.6
(n=9)
1 -18.9
(n=11)

5.4 – 53.2
(n=4)
10.2 – 40
(n=9)
8.8 - 95.8
(n=11)

1.6 – 5
(n=2)
1.3 – 8.1
(n=3)
2 -11.1
(n=8)

Table 3. Quantitative results for methadone and its metabolite 2-ethylidene-1,5-dimethyl3,3-diphenylpyrrolidine (EDDP) in meconium (n=9 total positive cases), placenta (n=6
total positive cases) and umbilical cord (n=6 total positive cases).
Matrix

Methadone (ng/g)

EDDP (ng/g)

Meconium

244.5 – 3,926 (n=7)

14.6 – 6,049 (n=9)

Placenta

42.1 – 366.3 (n=6)

5.1 – 1,975 (n=6)

Umbilical
Cord

4.3 – 763 (n=6)

1 – 143.2 (n=6)

Figure legends
Figure 1. Cocaine positive cases in hair segmented by trimesters (n=34) (A) and in hair
one 8 cm long segment (n=28) (B) above and below the Society of Hair Testing (SoHT)
cutoff compared to cocaine positive cases in meconium (n=9), placenta (n=6) and
umbilical cord (n=7).
Figure 2. Opioids positive (above and below SoHT cutoff) and negative (below method’s
limit of quantification) cases in hair segmented by trimesters (n=9 positive, n=9 negative)
(A) and in hair one 8cm long segment (n=5 positive, n=1 negative) (B) compared to
opioid positive cases in meconium (n=11), placenta (n=9) and umbilical cord (n=11).
Figure 3. Methadone positive (above and below 200 pg/mg cutoff) cases in hair
segmented by trimesters (n=6) (A) and in hair one 8 cm long segment (n=5) (B)
compared to cocaine positive cases in meconium (n=9), placenta (n=6) and umbilical
cord (n=6).

Supplemental Table 1. Limits of detection (LOD) and limits of quantification (LOQ)
for hair, meconium, umbilical cord and placenta in the employed methods21-23, and
cut-offs established by the Society of Hair Testing (SoHT cutoff) in hair. BE:
benzoylecgonine; CE; cocaethylene; OH-BE: hydroxyl-benzoylecgonine; 6-AM: 6acetylmorphine; M-3-G: morphine-3-glucuronide; M-6-G: morphine-6-glucuronide;
EDDP: 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine; A: amphetamine; MA:
methamphetamine; MDA: 3,4-methylenedioxyamphetamine; MDMA: 3,4methylenedioxymethamphetamine.
Analyte

Hair
(pg/mg)
LOD LOQ SoHT
cutoff
Cocaine
2
20
500
BE
10
20
50
CE
10
20
OH-BE
EME
Morphine
5
20
200
Codeine
2
20
6-AM
2
20
200
M-3-G
M-6-G
Methadone
2
20
EDDP
A
2
20
200
MA
2
20
200
MDA
2
20
200
MDMA
2
20
200

Meconium
(ng/g)
LOD LOQ
0.5
0.5
0.5
2.5
0.5
2.5
2.5
2.5
2.5
2.5
0.5
0.5
2.5
2.5
0.5
0.5

5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5

Umbilical Cord
(ng/g)
LOD
LOQ
0.5
0.5
0.5
0.75
0.5
0.75
1
0.75
1
1
0.5
0.5
0.75
0.75
0.5
0.5

1
1
1
1
1
1
2.5
1
2.5
2.5
1
1
1
1
1
1

Placenta
(ng/g)
LOD LOQ
0.5
0.5
0.5
0.5
0.75
0.75
0.75
0.75
2.5
2.5
0.5
0.5
2.5
0.5
1
0.75

1
1
1
1
2.5
1
1
1
5
5
1
1
5
1
2.5
1
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